Literature DB >> 2807003

Prognosis of the adenocarcinoma of the cervix uteri: a comparative study.

W Kleine1, K Rau, D Schwoeorer, A Pfleiderer.   

Abstract

The different prognoses for patients with adenocarcinomas and squamous cell carcinomas of the cervix uteri were proved by matched-pair analysis. One hundred forty-four patients with adenocarcinoma treated in 1964-1985 were compared in a ratio of 1:2 with 268 patients with squamous cell carcinoma comparable in age, stage, and treatment modality. In both groups 45% of patients were in stage I, 38% in stage II, 15% in stage III, and 2% in stage IV. Five- and 10-year survivals of patients with adenocarcinoma were significantly lower than for those with squamous cell carcinoma (53% resp. 42% vs 68% vs 58%, P = 0.006). In an analyses of patients' prognosis according to clinical stage there was no significant difference between both groups in stages III and IV treated exclusively by radiotherapy. No significant differences were found in stage I and II patients treated by radical surgery. However, the most significant difference in prognosis was seen in stage I and II patients treated by radiotherapy. Five-year survival was 58.6% in stage I adenocarcinomas compared with 85.0% in squamous cell carcinomas. It can be concluded from these results that a discussion of the problem of FIGO staging is more necessary than a discussion of the different radiosensitivities of these two histological types. Surgical treatment must have the same priority as radical surgery or staging laparotomy for exact histologic staging in adenocarcinomas of the cervix uteri.

Entities:  

Mesh:

Year:  1989        PMID: 2807003     DOI: 10.1016/0090-8258(89)90032-2

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  10 in total

1.  Increased expression of iASPP correlates with poor prognosis in FIGO IA2-IIA cervical adenocarcinoma following a curative resection.

Authors:  Fanming Kong; Xiaofeng Shi; Huzi Li; Pu Li; Jianchun Yu; XiaoJiang Li; Jun Chen; Yiyu Sun; Yingjie Jia
Journal:  Am J Cancer Res       Date:  2015-02-15       Impact factor: 6.166

Review 2.  Adenocarcinoma of the cervix: should we treat it differently?

Authors:  Ned L Williams; Theresa L Werner; Elke A Jarboe; David K Gaffney
Journal:  Curr Oncol Rep       Date:  2015-04       Impact factor: 5.075

3.  Reproductive factors and prognosis of uterine cervical cancer in Norway.

Authors:  T Bjørge; O Kravdal
Journal:  Br J Cancer       Date:  1996-12       Impact factor: 7.640

4.  Comparison of outcomes between squamous cell carcinoma and adenocarcinoma in patients with surgically treated stage I-II cervical cancer.

Authors:  Makoto Yamauchi; Takeshi Fukuda; Takuma Wada; Masaru Kawanishi; Kenji Imai; Yasunori Hashiguchi; Tomoyuki Ichimura; Tomoyo Yasui; Toshiyuki Sumi
Journal:  Mol Clin Oncol       Date:  2014-05-15

5.  High expression of CRAM correlates with poor prognosis in patients with cervical carcinoma.

Authors:  Teng Hou; Dongxia Liang; Dong Yang; Jiehua He; Yongwen Huang; Yanna Zhang
Journal:  Int J Clin Exp Pathol       Date:  2014-02-15

Review 6.  Primary surgery versus primary radiotherapy with or without chemotherapy for early adenocarcinoma of the uterine cervix.

Authors:  Astrid Baalbergen; Yerney Veenstra; Lukas Stalpers
Journal:  Cochrane Database Syst Rev       Date:  2013-01-31

7.  Safety and Prognostic Impacts of Ovarian Preservation during Radical Hysterectomy for Early-Stage Adenocarcinoma and Adenosquamous Cervical Cancer.

Authors:  Arisa Theplib; Jitti Hanprasertpong; Kittinun Leetanaporn
Journal:  Biomed Res Int       Date:  2020-11-12       Impact factor: 3.411

8.  A novel Silva pattern-based model for precisely predicting recurrence in intermediate-risk cervical adenocarcinoma patients.

Authors:  Chenyan Guo; Xiang Tao; Lihong Zhang; Ying Zhang; Keqin Hua; Junjun Qiu
Journal:  BMC Womens Health       Date:  2022-09-16       Impact factor: 2.742

9.  Prognostic value of histopathology and trends in cervical cancer: a SEER population study.

Authors:  Vincent Vinh-Hung; Claire Bourgain; Georges Vlastos; Gábor Cserni; Mark De Ridder; Guy Storme; Anne-Thérèse Vlastos
Journal:  BMC Cancer       Date:  2007-08-23       Impact factor: 4.430

10.  Estimate of the global burden of cervical adenocarcinoma and potential impact of prophylactic human papillomavirus vaccination.

Authors:  Jeanne M Pimenta; Claudia Galindo; David Jenkins; Sylvia M Taylor
Journal:  BMC Cancer       Date:  2013-11-21       Impact factor: 4.430

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.